Market News / Story
GSK-owned ViiV succeeds in late-stage trial for HIV therapy
Seeking Alpha ·
Seeking Alpha reports: ViiV Healthcare, an HIV treatment developer owned by GSK with Shionogi as an investor, announced on Tuesday that its long-acting HIV treatment Cabenuva succeeded in a late-stage trial. The company said that its Phase 3b CROWN trial reached the primary endpoint, as Cabenuva (cabotegravir + rilpivirine [CAB + RPV LA]) was associated with superior viral suppression compared with standard-of-care oral antiretrovirals at six months. The open-label trial ran across eight…